H3 K27M (diffuse midline glioma)
A single change in a histone protein that defines the most lethal childhood brain tumour, and now the target of the first approved drug for it.
Lysine-to-methionine mutation at position 27 of histone H3 (H3F3A or HIST1H3B) causes global loss of H3K27 trimethylation. Defines WHO grade 4 diffuse midline glioma (including DIPG), median survival ~11 months, radiotherapy the only proven therapy until dordaviprone (2025). GD2 is overexpressed, enabling CAR-T.
Pages like this
not linked directly; found by shared links- TermMGMT promoter methylation
Shares National Brain Tumor Society (NBTS), Epigenetic reprogramming, DNA methylation profiling, The brain: barrier and sanctuary.
- PersonStefan Pfister
Shares Develop drugs in children first when the target is a children's target, DNA methylation profiling, Glioma & glioblastoma.
- ProductVorasidenib
Shares National Brain Tumor Society (NBTS), Epigenetic reprogramming, The brain: barrier and sanctuary, Glioma & glioblastoma.
- IdeaNeoadjuvant immunotherapy with surgical window for glioblastoma
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
- TermEGFRvIII
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
- ProductTovorafenib
Shares Develop drugs in children first when the target is a children's target, The brain: barrier and sanctuary, Glioma & glioblastoma.
- IdeaDeliver CAR-T cells straight into the fluid around the brain
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.
- IdeaOpen the barrier so engineered immune cells can enter the brain
Shares CAR-T for glioma (IL13Rα2, GD2, EGFRvIII, multi-target), The brain: barrier and sanctuary, Glioma & glioblastoma.